Insight Molecular Diagnostics Inc. Marketing and Advertising Expense
Insight Molecular Diagnostics Inc. (IMDX) reported Marketing and Advertising Expense of $262.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:MarketingAndAdvertisingExpense · last filed 2026-08-10
- Insight Molecular Diagnostics Inc. marketing and advertising expense for the quarter ending 2026-06-30 was $262.00K, a 64.78% increase year-over-year.
- Insight Molecular Diagnostics Inc. marketing and advertising expense for the quarter ending 2026-03-31 was $135.00K, a 107.69% increase year-over-year.
- Insight Molecular Diagnostics Inc. marketing and advertising expense for the quarter ending 2025-12-31 was $261.00K, a 94.78% increase year-over-year.
- Insight Molecular Diagnostics Inc. marketing and advertising expense for the quarter ending 2025-09-30 was $97.00K, a 136.59% increase year-over-year.
- Insight Molecular Diagnostics Inc. marketing and advertising expense for fiscal 2025 was $582.00K, a 126.46% increase from fiscal 2024.
- Insight Molecular Diagnostics Inc. marketing and advertising expense for fiscal 2024 was $257.00K, a 37.43% increase from fiscal 2023.
- Insight Molecular Diagnostics Inc. marketing and advertising expense for fiscal 2023 was $187.00K.
| Period end | Marketing and Advertising Expense 3 month | Marketing and Advertising Expense 6 month | Marketing and Advertising Expense 9 month | Marketing and Advertising Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $262.00K 10-Q · filed 2026-08-10 | $397.00K 10-Q · filed 2026-08-10 | $658.00K derived: sum of 3 quarters · filed 2026-08-10 | $755.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $135.00K 10-Q · filed 2026-05-13 | $396.00K derived: sum of 2 quarters · filed 2026-05-13 | $493.00K derived: sum of 3 quarters · filed 2026-05-13 | $652.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $261.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $358.00K derived: sum of 2 quarters · filed 2026-03-26 | $517.00K derived: sum of 3 quarters · filed 2026-08-10 | $582.00K 10-K · filed 2026-03-26 |
| 2025-09-30 | $97.00K 10-Q · filed 2025-11-10 | $256.00K derived: sum of 2 quarters · filed 2026-08-10 | $321.00K 10-Q · filed 2025-11-10 | $455.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $159.00K 10-Q · filed 2026-08-10 | $224.00K 10-Q · filed 2026-08-10 | $358.00K derived: sum of 3 quarters · filed 2026-08-10 | $399.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $65.00K 10-Q · filed 2026-05-13 | $199.00K derived: sum of 2 quarters · filed 2026-05-13 | $240.00K derived: sum of 3 quarters · filed 2026-05-13 | $284.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $134.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $175.00K derived: sum of 2 quarters · filed 2026-03-26 | $219.00K derived: sum of 3 quarters · filed 2026-03-26 | $257.00K 10-K · filed 2026-03-26 |
| 2024-09-30 | $41.00K 10-Q · filed 2025-11-10 | $85.00K derived: sum of 2 quarters · filed 2025-11-10 | $123.00K 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $44.00K 10-Q · filed 2025-08-11 | $82.00K 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | $38.00K 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | $187.00K 10-K · filed 2025-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |